B
Bladström Anna
Researcher at Lundbeck
Publications - 8
Citations - 898
Bladström Anna is an academic researcher from Lundbeck. The author has contributed to research in topics: Nalmefene & Placebo. The author has an hindex of 5, co-authored 8 publications receiving 834 citations.
Papers
More filters
Journal ArticleDOI
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Murat Emre,Magda Tsolaki,Ubaldo Bonuccelli,Alain Destée,Eduardo Tolosa,Alexandra Kutzelnigg,Andres O. Ceballos-Baumann,Slobodan Zdravkovic,Bladström Anna,Roy W. Jones +9 more
TL;DR: In this paper, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB).
Journal ArticleDOI
Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
TL;DR: Nalmefene provides clinical benefit, constitutes a potential new pharmacological treatment paradigm in terms of the treatment goal and dosing regimen, and provides a method to address the unmet medical need in patients with alcohol dependence that need to reduce their alcohol consumption.
Journal ArticleDOI
Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies.
TL;DR: As-needed nalmefene was efficacious in reducing alcohol consumption in patients with at least a high drinking risk level at both screening and randomization, and the effect in this subgroup was larger than in the total population.
Journal ArticleDOI
Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
TL;DR: The post‐hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS‐cog single‐items or SIB subscales for patients with moderate to severe AD.
Journal ArticleDOI
Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.
Henri-Jean Aubin,Jens Reimer,David J. Nutt,Bladström Anna,Lars Torup,Clément François,Jonathan Chick +6 more
TL;DR: The clinical relevance of nalmefene treatment in patients with alcohol dependence is supported and may help to reduce the alcohol-related burden and the large treatment gap with currently less than 10% of alcohol-dependent patients in Europe receiving treatment.